Exploratory Clinical Trials for Small Business Grant Program
Page 2

That said, the NINDS seeks to provide support to small businesses in their quest to develop emerging technologies that will potentially be beneficial to the objective in focus.

The examples of the kinds of studies that will be supported under this program are those that aim to:

a) Evaluate and optimize the dose, formulation, safety, tolerability/pharmacokinetics of a certain intervention or diagnostic test in healthy volunteers or the target population

b) Prospective clinical validation of a diagnostic

c) Asses whether or not an intervention produces sufficient evidence of short-term activity in a human “proof of concept” trial

d) Determine the best of two or more potential interventions or dosing regimens that will be evaluated in a subsequent trial, based on tolerability, biological activity, or preliminary clinical efficacy.

The NIH and NINDS are set to administer a funding amount of $750,000 per grant awardee to support the execution of this program.

The institutions and organizations who will be considered eligible to submit an application under this program are those Small Business Concerns that meet the following criteria:

a) SBCs that are mainly organized for profit and is located and operating in the United States, and makes a substantial contribution to the United States economy through payment of taxes or use of American products, materials or labor;

b) SBCs that are in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative;

c) SBCs that does not have more than 500 employees

d) SBSs that are at least 51% owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States.

Exploratory Clinical Trials for Small Business Grant Program
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Mechanisms Mediating Osteoarthritis in Aging
The National Institutes of Health, in close cooperation with The National Institute on Aging and the National Institute of Arthritis and Musculoskeletal and Skin Diseases, has recently established a program called Mechanisms Mediating Osteoarthritis in Aging in an effort to improve and encourage the characterization of new and underutilized models in order to gain a deeper understanding of mechanisms that are involved in osteoarthritic progression.

---

Cancer Education Grants Program
The National Cancer Institute has developed the Cancer Education Grants Program wherein it seeks to financially support innovative educational efforts that would contribute to the reduction of cancer incidences, morbidity and mortality rates; as well as the improvement of the quality of life of surviving cancer patients.

---

Strategic Alliances for Medications Development to Treat Substance Use Disorder Program
The National Institutes of Health, in cooperation with the National Institute on Drug Abuse (NIDA), has recently established the Strategic Alliances for Medications Development to Treat Substance Use Disorder Program wherein both agencies seek to support the development of substance abuse drugs by leveraging the strengths of two or more organizations toward a common goal of medications development.

---

National Institutes of Health funds the Improving Adherence to Treatment Regimens for HIV-Positive Adolescents and Young Adults
The National Institutes of Health has recently established a program entitled Improving Adherence to Treatment Regimens for HIV-Positive Adolescents and Young Adults wherein they intend to kick-off research studies that will create, implement, and evaluate both old and new interventions that are geared towards improving adherence to medical and behavioral regimens for HIV-positive adolescents which are 11 to 21 years old and adults who are 21 to 24 years old.

---